(Q36268105)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16184618%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

review article

1 reference

title

Cardiovascular effects of the thiazolidinediones (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16184618%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16184618%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

Peter Schulman

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16184618%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

publication date

1 March 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16184618%20AND%20SRC:MED&resulttype=core&format=json

Diabetes - Metabolism: Research and Reviews

7 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16184618%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16184618%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16184618%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

88-97

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16184618%20AND%20SRC:MED&resulttype=core&format=json

Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state.

7 January 2020

cites work

1 reference

Essential Hypertension : Part I: Definition and Etiology

21 January 2018

1 reference

Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR).

21 January 2018

1 reference

Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus

21 January 2018

1 reference

Left ventricular concentric remodeling rather than left ventricular hypertrophy is related to the insulin resistance syndrome in elderly men.

21 January 2018

1 reference

Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats

21 January 2018

1 reference

Antiatherogenic effects of thiazolidinediones?

21 January 2018

1 reference

Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway

21 January 2018

1 reference

Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects

21 January 2018

1 reference

Expression and function of PPARgamma in rat and human vascular smooth muscle cells

21 January 2018

1 reference

Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion

21 January 2018

1 reference

High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

21 January 2018

1 reference

The role of carotid arterial intima-media thickness in predicting clinical coronary events

21 January 2018

1 reference

Troglitazone improves recovery of left ventricular function after regional ischemia in pigs

21 January 2018

1 reference

Coronary heart disease in patients with diabetes

21 January 2018

1 reference

7 January 2021

Decreased Insulin Secretion and Increased Insulin Resistance Are Independently Related to the 7-Year Risk of NIDDM in Mexican-Americans

1 reference

7 January 2021

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

1 reference

7 January 2021

Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis

1 reference

7 January 2021

Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes

1 reference

7 January 2021

Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma

1 reference

7 January 2021

Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats

1 reference

7 January 2021

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

1 reference

7 January 2021

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

1 reference

7 January 2021

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

1 reference

7 January 2021

Relationship of impaired glucose tolerance to left ventricular structure and function: The Strong Heart Study

1 reference

7 January 2021

Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes

1 reference

7 January 2021

Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo

1 reference

7 January 2021

Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes

1 reference

7 January 2021

Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

1 reference

7 January 2021

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

1 reference

7 January 2021

Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia

1 reference

7 January 2021

Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones

1 reference

7 January 2021

Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease

1 reference

7 January 2021

Impact of Weight Loss on Inflammatory Proteins and Their Association With the Insulin Resistance Syndrome in Morbidly Obese Patients

1 reference

7 January 2021

Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones

1 reference

7 January 2021

Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-delta and peroxisome proliferator-activated receptor-gamma

1 reference

7 January 2021

Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction

1 reference

7 January 2021

Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease

1 reference

7 January 2021

Soluble CD40L and cardiovascular risk in women

1 reference

7 January 2021

Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells

1 reference

7 January 2021

Troglitazone stimulates repair of the endothelium and inhibits neointimal formation in denuded rat aorta.

1 reference

7 January 2021

Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells

1 reference

7 January 2021

PPARgamma but not PPARalpha ligands are potent repressors of major histocompatibility complex class II induction in atheroma-associated cells

1 reference

7 January 2021

Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells

1 reference

7 January 2021

Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2

1 reference

7 January 2021

Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo

1 reference

7 January 2021

The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.

1 reference

7 January 2021

Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome

1 reference

7 January 2021

Atherosclerosis — An Inflammatory Disease

1 reference

7 January 2021

Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma

1 reference

7 January 2021

PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines

1 reference

7 January 2021

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

1 reference

7 January 2021

Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice

1 reference

7 January 2021

Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin

1 reference

7 January 2021

Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia

1 reference

7 January 2021

Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes

1 reference

7 January 2021

Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells

1 reference

7 January 2021

Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia

1 reference

7 January 2021

Unstable angina. A comparison of angioscopic findings between diabetic and nondiabetic patients

1 reference

7 January 2021

Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease

1 reference

7 January 2021

Regulation of MMP-1 expression in vascular endothelial cells by insulin sensitizing thiazolidinediones

1 reference

7 January 2021

Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease

1 reference

7 January 2021

Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones.

1 reference

7 January 2021

Relation between number of cardiovascular risk factors/events and noninvasive Doppler ultrasound assessments of aortic compliance

1 reference

7 January 2021

Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study

1 reference

7 January 2021

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

1 reference

7 January 2021

Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus

1 reference

7 January 2021

Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes

1 reference

7 January 2021

Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study

1 reference

7 January 2021

In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone

1 reference

7 January 2021

Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size

1 reference

7 January 2021

Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model

1 reference

7 January 2021

Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury

1 reference

7 January 2021

Deleterious effects of acute treatment with a peroxisome proliferator-activated receptor-gamma activator in myocardial ischemia and reperfusion in pigs

1 reference

7 January 2021

PPARs of the heart: three is a crowd

1 reference

7 January 2021

Apoptosis in myocytes in end-stage heart failure

1 reference

7 January 2021

Caspase inhibitors and myocardial apoptosis

1 reference

7 January 2021

Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion

1 reference

7 January 2021

Proinflammatory cytokines: predictors of a failing heart?

1 reference

7 January 2021

Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction

1 reference

7 January 2021

Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction

1 reference

7 January 2021

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

1 reference

7 January 2021

Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study

1 reference

7 January 2021

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study

1 reference

7 January 2021

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

1 reference

7 January 2021

Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

1 reference

7 January 2021

Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity

1 reference

7 January 2021

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.

1 reference

7 January 2021

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

1 reference

7 January 2021

Rosiglitazone in Type 2 diabetes mellitus: an evaluation in British Indo‐Asian patients

1 reference

7 January 2021

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

1 reference

7 January 2021

A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus

1 reference

7 January 2021

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

1 reference

7 January 2021

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

1 reference

7 January 2021

Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome.

1 reference

7 January 2021

The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients

1 reference

7 January 2021

Evidence for a potent antiinflammatory effect of rosiglitazone

1 reference

7 January 2021

Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.

1 reference

7 January 2021

Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes.

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.596

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16184618%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference